Reconsideration for current guideline of lipid-lowering therapy in patients with coronary artery disease.
10.4070/kcj.2001.31.8.767
- Author:
Ji Yean KO
1
;
Junghan YOON
;
Jang Young KIM
;
Bong Ki LEE
;
Hyun Min CHOE
;
Byung Su YOO
;
Seung Hwan LEE
;
Kyung Hoon CHOE
Author Information
1. Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Wonju, Korea.
- Publication Type:Original Article
- Keywords:
Coronary artery disease;
Secondary prevention;
Cholesterol-lowering therapy
- MeSH:
Cholesterol;
Cholesterol, LDL;
Coronary Artery Disease*;
Coronary Vessels*;
Education;
Humans;
Insurance;
Korea;
Logistic Models;
Secondary Prevention;
Triglycerides
- From:Korean Circulation Journal
2001;31(8):767-772
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: Despite the proven benefit of cholesterol- lowering therapy in patients with CAD, there is no consensual opinion on guideline of cholesterol-lowering therapy in patients with CAD in Korea. The aim of this study is to evaluate the risk of CAD according to the cholesterol level and to consider current guideline of cholesterol-lowering therapy for the secondary prevention in patients with CAD. MATERIALS AND METHODS: Consecutive 600 patients were assigned into two groups - coronary artery disease group (364 patients) and normal coronary artery group (236 patients) - depending on the coronary angiographic findings. Lipid profiles (total cholesterol, Triglyceride, HDL-cholesterol, LDL-cholesterol) were obtained and the odd ratio of CAD was evaluated according to the national cholesterol education program treatment guideline (NCEP: LDL cholesterol > or = 130 mg/dl) and the national heath insurance treatment guideline (NHI: total cholesterol > or = 220 mg/dl) by multi-variate logistic regression analysis. RESULTS: According to the NHI and NCEP guideline, the proportion of patients with CAD indicated on cholesterol-lowering therapy were 25%, 36.5% respectively and the odd ratio of CAD was 1.00 (95% CI 0.52 - 1.89, p=0.99), 4.89 (95% CI 2.78 - 8.60, p< 0.01) respectively . CONCLUSIONS: Our data showed that LDL-cholesterol > or = 130 mg/dl only reflected the risk of CAD in both guidelines and more proportion of the patients were indicated on cholesterol-lowering therapy in NCEP guideline than in NHI guideline.
